Clinical trials
Phase 2/3 Crohn Disease trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
27 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 1 |
| 2003 | 1 |
| 2005 | 2 |
| 2007 | 3 |
| 2008 | 1 |
| 2009 | 1 |
| 2011 | 1 |
| 2014 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 3 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 3 |
| 2023 | 2 |
| 2024 | 1 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 8 |
| Unknown status | 7 |
| Terminated | 6 |
| Recruiting | 2 |
| Withdrawn | 2 |
| Enrolling by invitation | 1 |
| Active, not recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Abbott | 2 |
| Children's Hospital Medical Center, Cincinnati | 2 |
| Janssen Research & Development, LLC | 2 |
| Nationwide Children's Hospital | 2 |
| Sixth Affiliated Hospital, Sun Yat-sen University | 2 |
| University of Aarhus | 2 |
| Abivax S.A. | 1 |
| Altschuler, Eric, M.D. | 1 |
| Assistance Publique - Hôpitaux de Paris | 1 |
| AstraZeneca | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Crohn Disease | 27 |
| Inflammatory Bowel Diseases | 7 |
| Colitis, Ulcerative | 3 |
| Arthritis, Juvenile | 2 |
| Chronic Disease | 1 |
| Dermatomyositis | 1 |
| Digestive System Diseases | 1 |
| Dwarfism | 1 |
| Failure to Thrive | 1 |
| Fistula | 1 |
Trials
Showing 1 to 25 of 27. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.